GALDERMA
Galderma today announced a European re-launch of Sculptra ® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra ® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product. Sculptra ® now has the fastest reconstitution protocol of any injectable poly-L-lactic acid (PLLA) available in Europe, representing a significant growth opportunity for Galderma.
“Sculptra ® has been my go-to tool for treating skin laxity resulting from aging and collagen loss in my patients’ skin, helping restore a youthful appearance,” said Dr. Christoph Martschin, Dermatologist, Akademikliniken, Department of Dermatology, Stockholm, and a featured speaker at the Sculptra ® European re-launch virtual event. “This new reconstitution protocol for Sculptra ® represents an exciting benefit as we are able to save valuable clinic time for clinicians while improving overall procedure comfort for our patients.”
Collagen provides structure and support to the skin. With facial aging, the skin’s natural collagen supply may decrease and could lead to skin laxity, wrinkles and roughness as skin quality worsens.1,2 Sculptra ® is a collagen stimulator that may help replenish lost collagen by gradually stimulating and increasing an individual’s own natural collagen production, helping restore skin quality and firmness.2-5
The updated protocol is based on new data from physiochemical studies,6 as well as results from a randomized, evaluator-blinded, parallel-group, multi-center study (NCT03780244) evaluating the safety and effectiveness of two different dilutions of Sculptra ® . This study demonstrated that treatment immediately following a two-minute reconstitution using the higher reconstitution volume (9 mL including lidocaine) was well tolerated, caused less pain on injection and was comparable to that of the reference group (Sculptra ® 5 mL) in reducing wrinkle severity of nasolabial folds (NLF) at Week 48 (n=80). Additionally, the mean change in wrinkle assessment scale (WAS) from baseline (assessed by Blinded Evaluator) was similar in both Sculptra ® study groups across 48 weeks and investigator assessed improvement using the Global Aesthetic Improvement Scale (GAIS) was > 90% in both Sculptra ® study groups.
As part of this European re-launch and in line with the company’s intensified commitment to Sculptra ® , Galderma held a dedicated interactive, virtual event with over 1,000 healthcare professionals to provide additional training and support related to this new administration protocol. The event also facilitated best practice sharing among physicians based on their clinical experiences.
“We are delighted to bring this expanded Sculptra ® offering to healthcare professionals in Europe, and yesterday’s launch event was an exciting, well-attended re-introduction to Sculptra ® and Galderma’s larger aesthetics portfolio,” said Alexandre Brennan, Global Business Unit Head, Aesthetics. “We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to re-launch Sculptra ® in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients.”
Sculptra ® was first approved in Europe in 1999, in the United States in 2009 and in Brazil in 2004. Sculptra ® is now available in more than 40 countries globally, and additional regulatory reviews of applications for Sculptra ® in various regions are ongoing.
About Sculptra
®
Sculptra
®
works to stimulate the skin’s own collagen production and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, scars and for skin aging. Sculptra
®
is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).
Sculptra ® is an injectable biostimulator containing microparticles of Poly-L-Lactic Acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months. Sculptra ® was first approved in 1999 in Europe and it is currently available in more than 40 countries globally. To learn more about Sculptra ® products, visit www.galdermaaesthetics.com
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in approximately 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with healthcare professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
- Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93:639-643.
- Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684–92.
- Stein P et al. J Dermatol Sci 2015;78(1):26–33.9.
- Goldberg D et al. Dermatol Surg 2013;39(6):915–22.
- Vleggaar D et al. J Drugs Dermatol 2014;13 (4 suppl):s29–31.
- Baumann K et al. J Drugs Dermatol. 2020;19(12):1199-1203.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303006096/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
IEEE Standards Commitment to Advancing AI Governance Includes Impactful Contributions to New International AI Standards Exchange11.7.2025 08:00:00 CEST | Press release
IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and its IEEE Standards Association (IEEE SA) announced today that its portfolio of over 100 global AI-related standards is included in the new International AI Standards Exchange. This Exchange is a centralized repository of international AI standards with the aim to foster collaboration and responsible AI development worldwide. IEEE and its AI global standards were recognized in the 2024 United Nations AI Advisory Body’s Report, Governing AI for Humanity, which created the impetus for the AI Standards Exchange. Due to its impactful AI standards and related work, IEEE, a major standards body, was included as a partner in the establishment of the Exchange. IEEE President and CEO Kathleen Kramer, who is speaking at the AI for Good Summit this year at the High-Level AI Standards Panel,shares, “IEEE’s mission of advancing technology for the benefit of humanity is foundational to ou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom